STERIS plc STE
Composite 58/100; the shares have moved about 27% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 37/100 — a moderate mark against it.
Balance-sheet strength ranks 78/100 — a strong point in its favour. Growth ranks 68/100 — a moderate point in its favour. Quality ranks 64/100 — a moderate point in its favour.
Valuation ranks 37/100 — a moderate mark against it. Momentum ranks 45/100 — a slight mark against it. Income ranks 46/100 — a slight mark against it.
What the company does STERIS plc (STE) provides infection prevention products and services, including sterilization equipment, endoscope reprocessing systems, and life sciences solutions across Healthcare, Applied Sterilization Technologies, and Life Sciences segments.
Key financials STERIS reports strong profitability with gross margins at 44.4%, operating margins at 19.1%, and net margins at 13.3%. ROE is 11.4%, ROA 6.8%, and ROCE 12.1%. Revenue growth is 8.7% with EPS growth of 27.9%. The company maintains a solid balance sheet with a debt/equity ratio of 0.28 and interest coverage of 18.80.
Stock health The stock shows mixed momentum: up 11.56% over 3 months but down -5.62% over 6 months and -3.94% over 12 months. It is -11.64% below its 52-week high, with an RSI(14) of 59.70 indicating neutral momentum. SIDERAVIA scores Quality 63.8, Growth 70.6, and Strength 78.9, reflecting above-average fundamentals.
Price vs fair value STERIS trades at a **discount of 11.10%** versus the analyst mean target of 263.12. - Trading at a discount to analyst mean target (Barchart). - Forward P/E of 21.46 and PEG of 0.66 suggest undemanding valuation metrics. - Valuation percentile of 37.0/100 indicates fair value relative to peers. - SIDERAVIA Valuation score of 37.0 reinforces the fair-value assessment.
Looking forward Forward P/E of 21.46 and EV/EBITDA of 15.15 suggest modest valuation relative to earnings growth. Analysts highlight potential upside amid healthcare sterilization demand, though recent stock performance has lagged. The company’s strong profitability and balance sheet support steady long-term growth.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.